Gregory Merril was the founding CEO of Adaptive Phage Therapeutics (APT) now BiomX (NYSE: PHGE) where he continues to serve on the Board of Directors. At APT, he pioneered a method for delivering personalized antimicrobial phage therapy at scale and established a first-in-class GMP manufacturing facility. Additionally, Greg successfully implemented an AI/ML team that developed a system to rapidly predict the efficacy of phages in treating AMR infections and formed a collaboration with Mayo Clinic Laboratories with a goal to make personalized phage therapy globally accessible. Prior to APT, he was the founding CEO of HT Medical Systems, focusing on computer-based surgical training simulators (now Immersion Corp, NASDAQ: IMMR). Greg is a prolific inventor with 22 issued patents. Currently, he lends his expertise to various startups, taking on roles from strategic advisor to Executive Director.